Dafinchi AI

VREX

Healthcare

Adjusted EBITDA was $29 million for the quarter, with a trailing 12-month adjusted EBITDA of $110 million and net debt leverage ratio of approximately 2x.
Cash and equivalents ended at $153 million, down $73 million due to repayment of $200 million convertible notes.
GAAP results included a $94 million goodwill impairment charge, resulting in an operating loss of $81 million and net loss of $89 million.
Medical segment revenue declined 4% to $142 million, while Industrial segment revenue increased 1% to $61 million.
Non-GAAP EPS was $0.18, up $0.04 from the prior year quarter.
Non-GAAP gross margin was 34%, 100 basis points higher than the prior year and above guidance expectations.
Varex reported Q3 FY2025 revenue of $203 million, slightly down 3% year-over-year but above the high end of guidance.

MNKD

Healthcare

Afrezza net revenues increased 13% to $18 million in Q2, driven by growth in new and recurring prescriptions.
Collaboration and services revenue declined 12% to $23 million due to timing of manufacturing and one-time items.
Q2 2025 revenues reached $77 million, a 6% increase over Q2 2024, with year-to-date revenues of $155 million, up 12% from 2024.
The company ended Q2 with a strong cash position of $201 million and secured up to $500 million in nondilutive capital from Blackstone.
Tyvaso DPI royalties grew 22% year-over-year to $31 million in Q2, contributing significantly to revenue growth.
V-Go net revenue decreased 8% to approximately $4 million, reflecting lower product demand and lack of active promotion.

Earnings Feed